FDA Expects Consent Decree For GSK As Follow-Up To Seizure Action
Executive Summary
FDA expects to enter into a consent decree with GlaxoSmithKline to resolve manufacturing violations at its Cidra, Puerto Rico facility following the seizure of Paxil CR and Avandamet
You may also be interested in...
Paxil CR returns
GlaxoSmithKline resumes shipment of Paxil CR, four months after manufacturing problems led to FDA's seizure of the product at distribution and production facilities (1"The Pink Sheet" March 21, 2005, p. 15). Sales reps will offer 30-day free trial vouchers to support reintroduction; Paxil CR will be a "priority" for sales force, GSK says. Resupply of Avandamet, which also was seized by FDA, is projected to begin by mid-July...
Paxil CR returns
GlaxoSmithKline resumes shipment of Paxil CR, four months after manufacturing problems led to FDA's seizure of the product at distribution and production facilities (1"The Pink Sheet" March 21, 2005, p. 15). Sales reps will offer 30-day free trial vouchers to support reintroduction; Paxil CR will be a "priority" for sales force, GSK says. Resupply of Avandamet, which also was seized by FDA, is projected to begin by mid-July...
FDA Regulatory Affairs Head Glavin Brings Counterterrorism, Food Experience
FDA's new Associate Commissioner for Regulatory Affairs Margaret Glavin brings a background in food safety and bioterrorism to the post